By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
How federal officials talk about health is shifting in troubling ways – and that change makes me worried for my autistic child - 2Gulf countries continue to face Iran attacks as criticial energy infrastructure at risk
- 3Step by step instructions to Contrast Lab Precious stones and Normal Jewels
- 4The Ascent of the Kona SUV: How Hyundai's Reduced Hybrid Is Vanquishing the Streets
- 5Vote In favor of Your Number one Savvy Beds
- Step by step instructions to Safeguard Your Teeth During Sports Exercises
- Merz: 80% of Syrians in Germany should return in three years
- Fact Check: Israeli Channel 13, Al Jazeera Did NOT Confirm Hezbollah Captured All Or Part Of Kiryat Shmona
- Hundreds of Intact Dinosaur Eggs Emerge From 72-Million-Year Time Capsule
- Golan resident convicted of spying for Iran after passing tank movement, missile-impact data
- Medicine doesn’t just have ‘conscientious objectors’ − there are ‘conscientious providers,’ too
- Pick Your Favored kind of soup
- Zendaya serves bridal-coded fashion with old, new and borrowed gowns for ‘The Drama’ press tour
- How did life begin on Earth? New experiments support 'RNA world' hypothesis
